育龄期子宫肌瘤剔除术患者子宫肌瘤的系统分子与临床分析
该回顾性研究分析了234例≤45岁行子宫肌瘤剔除术患者的361份子宫肌瘤样本,发现已知驱动突变占肿瘤的83%(MED12 71%、HMGA2 9%、FH 3%);单发肌瘤中MED12突变频率仅43%,29%为全野生型;MED12突变与多发肌瘤、较小肿瘤及浆膜下位置相关。
要点
- 育龄期肌瘤剔除患者中83%的肌瘤携带MED12、HMGA2或FH驱动突变。
- 单发肌瘤的MED12突变频率为43%,29%为全野生型。
- MED12突变与多发肌瘤、较小肿瘤及浆膜下位置相关。
核心结论
- 育龄期肌瘤剔除患者肌瘤中驱动突变的贡献与中年女性子宫切除术标本相当。
- 研究结果支持MED12突变与多发肌瘤、较小肿瘤及浆膜下位置相关的既往发现。
- 单发肌瘤具有独特的分子背景,需更多研究阐明相当比例野生型肌瘤的 underlying 原因。
研究设计与样本
- 回顾性系列分析234例2009-2014年间行子宫肌瘤剔除术的≤45岁女性的361份存档子宫肌瘤样本。
主要发现
- 手术中位年龄为34岁。
- 58%的患者因单发肌瘤接受手术。
- 83%的肿瘤存在已知驱动突变(MED12 71%;HMGA2 9%;FH 3%)。
- 单发肌瘤中MED12突变频率仅43%,29%对所有驱动突变均为野生型。
- MED12突变与多发肿瘤、较小肿瘤尺寸及浆膜下位置相关。
局限性
- 研究为回顾性 nature,所有样本均为常规诊断目的收集。
- 使用石蜡包埋样本和免疫组化可能导致突变被低估。
- 由于样本量有限且尤其FH缺陷型肌瘤罕见,数据部分为描述性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What are the distributions and associated clinical characteristics of mediator complex subunit 12 (MED12), high mobility group AT-hook 2 (HMGA2) and fumarate hydratase (FH) aberrations in uterine leiomyomas from fertile-aged myomectomy patients? SUMMARY ANSWER: These driver mutations account for the majority (83%) of tumours in fertile-aged patients. WHAT IS KNOWN ALREADY: Alterations affecting MED12, HMGA2 and FH account for 80-90% of uterine leiomyomas from middle-aged hysterectomy patients, while the molecular background of tumours from young myomectomy patients has not been systematically studied. STUDY DESIGN, SIZE, DURATION: A retrospective series of 361 archival uterine leiomyoma samples from 234 women aged ≤45 years undergoing myomectomy in 2009-2014 was examined. Associations between the molecular data and detailed clinical information of the patients and tumours were analysed. PARTICIPANTS/MATERIALS, SETTING, METHODS: DNA was extracted from formalin-fixed paraffin-embedded samples and MED12 exons 1 and 2 were sequenced to identify mutations. Level of HMGA2 expression was evaluated by immunohistochemistry. Biallelic FH inactivation was analysed with 2-succinylcysteine staining, which is an indirect method of assessing FH deficiency. All patients' medical histories were reviewed, and clinical information of patients and tumours was combined with molecular data. MAIN RESULTS AND THE ROLE OF CHANCE: The median age at operation was 34 years. The majority (58%) of patients were operated on for a single leiomyoma. Known driver mutations were identified in 83% of tumours (71% MED12; 9% HMGA2; 3% FH). In solitary leiomyomas, the MED12 mutation frequency was only 43%, and 29% were wild-type for all driver alterations. MED12 mutations were associated with multiple tumours, smaller tumour size and subserosal location. LIMITATIONS, REASONS FOR CAUTION: Although comprehensive, the study is retrospective in nature and all samples have been collected for routine diagnostic purposes. The use of paraffin-embedded samples and immunohistochemistry may have led to an underestimation of mutations. Due to the limited sample size and rarity of especially FH-deficient leiomyomas, the data are partly descriptive. WIDER IMPLICATIONS OF THE FINDINGS: The contribution of driver mutations in leiomyomas from young myomectomy patients is comparable to tumours obtained from hysterectomies of mostly middle-aged women. Our results support the earlier findings that MED12 mutations are associated with multiple tumours, smaller tumour size and subserosal location. The study emphasizes the distinct molecular background of solitary leiomyomas, and more research is needed to clarify the underlying causes of the notable proportion of wild-type leiomyomas. STUDY FUNDING/COMPETING INTEREST(S): The study was supported by the Academy of Finland (307773), the Sigrid Jusélius Foundation, the Cancer Foundation Finland and the iCAN Digital Precision Cancer Medicine Flagship. The authors declare no conflicts of interest. TRIAL REGISTRATION NUMBER: N/A.
引用
- Äyräväinen A, Pasanen A, Ahvenainen T, et al. Systematic molecular and clinical analysis of uterine leiomyomas from fertile-aged women undergoing myomectomy. Hum Reprod. 2020. PMID: 32829387. doi:10.1093/humrep/deaa187
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。